NASDAQ HAS BEEN GETTING HAMMERED THE LAST FEW SESSIONS, AND I FOND THIS AS WELL.
SHOULD SEE A NICE POP TOMORROW AS LONG AS TH NASDAQ FOLLOWS.
In company news, Response Genetics ( RGDX ) shares climbed Monday after a regulatory filing showed activist investor Becker Drapkin Management LP reduced its stake last week in the developer of clinical diagnostic tests for cancer by over one third.
RGDX was up 1.6% at $1.31 in recent trading, just 3 cents off its intra-day high. The stock has a 52-week range of $1.09 to $2.93 a share.
The April 4 filing showed Becker Drapkin now holds 1.35 million shares, down from 2 million shares in February after selling a total of 675,643 shares last Thursday and Friday. The fund now owns about 3.5% of RGDX stock, down from its previous 5.9% stake.
Becker Drapkin's individual members - Steven R. Becker and Matthew A Drapkin - currently own 181,679 and 114,504, respectively, unchanged from the previous filing